The treatment of autoimmune hepatitis

Current Clinical Pharmacology

Volumn 7, Issue 4, 2012, Pages 318-327

  Malnick, Stephen ^a   Duek, Gabriel ^a   Melzer, Ehud ^a   Basevitz, Alon ^a  

^a KAPLAN MEDICAL CENTER   (Israel)

Author keywords

Autoimmune hepatitis; Treatment

Indexed keywords

6 TG; ALKALINE PHOSPHATASE; AUTOANTIBODY; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CORTISONE; CYCLOSPORIN A; IMMUNOGLOBULIN G; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ACNE; ACUTE PANCREATITIS; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASYMPTOMATIC DISEASE; AUTOIMMUNE HEPATITIS; BONE MARROW TOXICITY; BRAIN LYMPHOMA; CATARACT; CHOLESTASIS; CORTICOSTEROID THERAPY; CUSHING DISEASE; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; ENTERITIS; FLU LIKE SYNDROME; GENERALIZED EDEMA; GINGIVA HYPERTROPHY; HIGH RISK POPULATION; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LIVER HISTOLOGY; LIVER TOXICITY; LIVER TRANSPLANTATION; LOW DRUG DOSE; MENTAL DISEASE; MUSCLE ATROPHY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OBESITY; OPPORTUNISTIC INFECTION; OSTEOPENIA; OSTEOPOROSIS; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; RASH; REMISSION; SIDE EFFECT; STRIA; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT RESPONSE; TREMOR; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION; VOMITING;

EID: 84867805594     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488412803305812     Document Type: Article

References (124)

1. Ngu JH, Bechly K, Chapman BA, et al. Population-based epidemiology study of autoimmune hepatitis-a disease of older women? J Gastoenterol Hepatol 2010; 25: 1681-6.
2. Zolfino T, heneghan MA, Norris S, Harrison PM, Portmann BC, McFarlane IG. Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut 2002; 50: 713-7.
3. Nakamura K, Yoneda M, Yokohama S, et al. Efficacy of ursodexoycholic acid in Japanese patients with type I autoimmune hepatitis. J Gastroenterol Hepatol 1998; 13: 490-5.
4. Teufel A, Weinmann A, Kahaly GJ, et al. Concurrent autoimmune disease in patients with autoimmune hepatitis. J Clin Gastroenterol 2010; 44: 208-13.
5. Kogan J, Safadi R, Ashur Y, et al. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol 2002; 35: 75-81.
6. Feld JJ, Dinh H, Arenovich, et al. Autoimmune hepatitis; effects of symptoms and cirrhosis on natural history and outcome. Hepatology 2005; 42: 53-62.
7. Werner M, Wallerstedt S, Lindgren S, et al. Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response. Scand J Gastroenterol 200; 45: 457-67.
8. Donaldson PT, Doherty DG, Hayllar KM, et al. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991; 13: 701-6.
9. Seki T, Kiyosawa K, Inoko H, Ota M. Association of autoimmune hepatitis with HLA-Bw54 and DR4 in Japanese patients. Hepatology 1990; 12: 1300-4.
10. Huppertz H-I, Treichel U, Gassel AM, et al. Autoimmune hepatitis following hepatitis A infection. J Hepatol 1995; 23: 204-8.
11. Vento S, Cainelli F, Renzini C, et al. Autoimmune hepatitis type 2 induced by HCV and persisting after viral clearance. Lancet 1997; 350: 1298-9.
12. ndedition. Amsterdam: Elsevier, 1998: 627-49.
13. Sterling MJ, Kane M, Grace ND. Pemoline-induced autoimmune hepatitis. Am J Gastroenterol 1996; 91: 2233-4.
14. Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosuslike syndrome. BMJ 1996; 312: 169-72.
15. Nietsch HH, Libman BS, Pansze TW, et al. Minocycline-induced hepatitis. Am J Gastroenterol 2000; 95: 2993-5.
16. Graziadei IW, Obermoser GE, Sepp NT, Erhart KH, Vogel W. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus 2003; 12: 409-12.
17. Silveira MG, Lindor KD. Overlap syndromes with autoimmune hepatitis in chronic cholestatic liver diseases. Expert Rev Gastroenterol Hepatol 2007; 1: 329-40.
18. Baeres M, herkel J, Czaja AJ, et al. Establishment of standardized SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence and clinical characteristics. Gut 2002; 51: 259-64.
19. Manns M, Gerken G, Kryiatsoulis A, Staritz M, Meyer zum Buschenfelde KH. Characteristics of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987; 1: 292-4.
20. Czaja A, Manns M. Advances in the diagnosis, pathogenesis and management of autoimmune hepatitis. Gastroenterology 2010; 139: 58-72.
21. Miyake Y, Iwasaki Y, Kobashi H, et al. Autoimmune hepatitis with acute presentation in Japan. Dig Liver Dis 2010; 42: 51-4.
22. Alvarez F, Berg PA, Bianchi FB, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.
23. Toda G, Zeniya M, Watanabe F, et al. Present status of autoimmune hepatitis in Japan-correlating the characteristics with international criteria in an area with a high rate of HCV infection. Japanese National Study Group of Autoimmune Hepatitis. J Hepatol 1997; 26: 1207-12.
24. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria ofr the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-76.
25. Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology 2008; 48: 1540-8.
26. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002; 36: 479-97.
27. Cook, GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 158: 159-85.
28. Soloway RD, Summerskill WHJ, Archie H, et al. Clinical, biochemical and histological remission of severe chronic active liver disease. A controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 820-33.
29. Murray-Lyon IM. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; 735-7.
30. Roberts SK, Therneau TM, Czaja JA. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996; 110: 848-57.
31. Czaja JA, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004; 40: 646-52.
32. Cotler SJ, Jakate S, Jensen DM. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J Clin Gastroenterol 2001; 32: 428-30.
33. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002; 36; 479-97.
34. Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007; 102: 1005-12.
35. Coverdale SA, Field J, Farrell GC. How reversible is hepatic functional impairment in autoimmune hepatitis? J Gastroenterol Hepatol 2003; 18: 371-5.
36. Schalm W, Summerskill WHJ, Go VLW. Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisone. Gastroenterology 1977; 72: 910-3
37. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-213.
38. Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 2002; 35: 7-13.
39. Buchanan AL. Side effects of corticosteroid therapy. J Clin Gastro 2001; 33: 289-94.
40. Czaja A. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf 2008; 7: 319-33.
41. Tomlinson JW, Walker EA, Bujalska IA, et al. 11_-hydroxysteroid dehydrogenase type 1: A tissue-specific regulator of glucocorticoid response. Endocr Rev 2004; 25: 831-6
42. Collier J. Bone disorders in chronic liver disease. Hepatology 2007; 46: 1271-8.
43. Pares A, Guanabens N. Treatment of bone disorders in liver disease. J Hepatol 2006; 45: 445-53.
44. Leslie WD, Bernstein CN, Leboff MS. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003; 125941-66.
45. Gleeson D, Heneghan M. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut 2011; 60: 1611-29.
46. Royal College of Physicians. Glucocorticoid Induced Osteoporosis: Guidelines for prevention and treatment. London: Royal College of Physicians, 2002.
47. Elion GB. The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine. Ann NY Acad Sci 1993; 685: 400-7.
48. Banerjee S, Rahhal R, Bishop WP. Azathioprine monotherapy for maintenance of remission in pediatric patients with autoimmune hepatitis. J Pediatr Gastroenterol Nutr 2006; 43: 253-6.
49. Stellon AJ, Hegarty JE, Portmann B, Williams R. Randomized controlled trial of azathioprine withdrawal in autoimmune chronic active hepatitis. Lancet 1985; I: 668-70.
50. Hindorf U, Jahed K, Bergquist A, et al. Characterization and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. J Hepatol 2010; 52: 106-11.
51. Heneghan MA, Allan ML, Bornstein JD, Muir AJ, Tendler DA. Utility of thiopurine methyltransferase genotyping and phenotyping and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol 2006; 45: 584-91.
52. Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology 2006; 43: S132-44.
53. Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type I autoimmune hepatitis and predictive model of end-stage liver disease. Hepatology 2007; 46: 1138-45.
54. Miyake Y, Yamamoto K. Current status of autoimmune hepatitis in Japan. Acta Med Okayama 2008; 62: 217-26.
55. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000; 31: 1231-8.
56. Toruner M, Loftus EV Jr Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-36
57. Seksik P, Cosnes J, Sokol H, et al. Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine. Aliment Pharmacol Ther 2009; 29: 1106-13
58. Vijayan VK. Parasitic lung infections. Curr Opin Pulm Med 2009; 15: 274-82.
59. Malnick S, Somin M, Beilinson N, Basevitch A, Bregman G, Zimhony O. Strongyloides hyperinfection in Ethiopian immigrants in Israel. Isr Med Assoc J 2009; 11: 660-3.
60. Bichari W, Bartiromo M, Mohey H, et al. Significant risk factors for occurrence of cancer after renal transplantation: a single center cohort study of 1265 cases. Transpl Proc 2009; 41: 672-3
61. Bernstein CN, Blanchard JF, Kliewer E, Wadja A. Cancer risk in patients with inflammatory bowel disease. Cancer 2001; 91: 854-62
62. Hegarty JE, Nouri Aria KT, Portmann B, Eddleston AL, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 1983; 3: 685-9.
63. Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver International 2003; 23: 116-23.
64. Kanzler S, Gerken G, Lohr H, et al. Duration of immunosuppressive therapy in autoimmune hepatitis (letter to the editor). J Hepatol 2001; 34: 354-5.
65. Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver International 2007; 27; 507-15.
66. Golshayan D, Pascual M, Vogt B. Mycophenolic acid formulations in adult renal transplantation-update on efficacy and tolerability. Ther Clin Risk Manag 2009; 5: 341-51.
67. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
68. Ransom JT. Mechanism of action of mycophenolate mofetil. Ther Drug Monit 1995; 17: 681-4.
69. Schuppan D, Schneider HT, Hahn EG. Successful treatment of therapy-refractory autoimmune hepatitis with mycophenolate motefil. Hepatology 1998; 28: A1960.
70. Richardson PD, James PD, Ryder SD. Mycophenolate motefil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000; 33: 371-5.
71. Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004; 18: 321-6.
72. Brunt EM, Di Bisceglie AM, Histological changes after the use of mycophenolate in autoimmune hepatitis. Hum Pathol 2004; 35: 509-12.
73. Chatur N, Ramji A, Bain VG, et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian Association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 2005; 25: 723-7.
74. Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol 2005; 39: 819-25.
75. Inductivo-Yu I, Adams A, Gish RG, et al. Mycophenoalte mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol 2007; 5: 799-802.
76. Hlivko JT, Shiffman ML, Stravitz RT, et al. A single center review of the use of myclophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008; 6: 1036-40.
77. Hennes EM, Oo YH, Schramm C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 2008; 103: 3063-70.
78. Wolf DC, Bojito L, Facciuto M, Lebovics E. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience. Dig Dis Sci 2009; 54: 2519-22.
79. Baven-Pronk AMC, Loenraad MJ, van Bauren HR, et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Therap 2011; 34: 335-43.
80. Sharzei K, Huang MA, Schreibman IR, Brown KA. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to or intolerant to conventional therapy. Can J Gastroenterol 2010; 24: 588-92.
81. Zachou K, Gatselis N, Papandamou G, et al. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficiency and safety for induction and, maintenance of remission in a large cohort of treatment-naïve patients. J Hepatol 2011; 55: 636-46.
82. Buell C, Koo J. Long-term safety of mycophenolate mofetil and cyclosporine: a review. J Drugs Dermatol 2008; 7: 741-8
83. Finelli PF, Nail K, DiGiuseppe, et al. Primary lymphoma of CNS, mycophenolate mofetil and lupus. Lupus 2006; 15: 886-8.
84. Hamedani R, Feldman RD, Feagan BD. Review article: Drug development in inflammatory bowel disease: budesonide-a model of targeted drug therapy. Aliment Pharmacol Ther 1997; 11 (Suppl 3): 98-107.
85. Csepregi A, Rocken C, Treiber G, Malfertheiner P. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol 2006; 12: 1362-.
86. Wiegand J, Schuler A, Kanzler S, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int 2005; 25: 927-34.
87. Zandieh I, Krygier D, Wong V, et al. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can J Gastrenterol 2008; 22: 388-.
88. Manns MP, Woynarowski M, Kreisel W, et al. Azathioprine with budesonide induces remission more effectively than with prednisone in patients with autoimmune hepatitis. Gastroenterology 2010; 139: 1198-206.
89. Geier A, Gartung C, Dietrich CG, et al. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versusportosystemic shunts on a patient complicated with HCC. World J Gastroenterol 2003; 9: 2681-5.
90. Heathcote EJ. Management of primary biliary cirrhosis. Hepatology 2000; 31: 1005-13.
91. Trauner M, Graziadei IW. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol Ther 1999; 13: 979-96.
92. Czaja A, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 1999; 30: 1381-6.
93. Miyake Y, Iwasaki Y, Kobashi H, et al. Efficacy of urosdeoxycholic acid for Japanese patients with autoimmune hepatitis. Dig Liver Dis 2010: 42: 210-5.
94. Beuers U, Rust C. Overlap syndromes. Semin Liver Dis 2005; 25: 311-20.
95. Geissler EK, Schlitt HJ. Immunosuppression for liver transplantation. Gut 2009; 58: 452-63.
96. Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, et al. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 2001; 46: 1321-7.
97. Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in pateints with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999; 94: 241-8.
98. Alvarez F, Ciocca M, Canero-Velasco C, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol1999; 30: 222-7.
99. Fagiuoli S, Bruni F, Bravi M, et al. Cyclosporin in steroid-resistant autoimmune hepatitis and HCV-related liver diseases. Dig Liver Dis 2007; 39: (Suppl 3) S379-85.
100. Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol 1994; 21: 1040-7.
101. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481-509.
102. Hooks MA. Tacrolimus, a new immunosuppressant-a review of the literature. Annals Pharmacotherapy 1994; 28: 501-11.
103. Larsen FS, Vainer B, Eefsen M, Bjerring PN, Adel Hansen B. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid-refractory autoimmune hepatitis. World J Gastroenterol 2007; 13: 3232-6.
104. Aquel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004; 38: 805-9.
105. Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 2002; 35: 7-13.
106. Pratt DS, Flavin DP, Kaplan MM. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathiopurine. Gastroenterology 1996; 110: 271-4.
107. De Boer NK, van Nieuwkerk CM, Aparicio PNM, et al. Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine. Eur J Gastroenterol Hepatol 2005; 17: 457-61.
108. De Jong DJ, Derijks LJ, Naber AH, Hooymans PM, Mulder CJ. Safety of thipurines in the treatment of inflammatory bowel disease. Scand J Gastroenterol Suppl 2003; 69-72.
109. Santos ESAL, Raez LE, O'Brien C, Regev A. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of the literature. Liver Int 2006; 26: 625-9.
110. Evans JT, Oates JC, Self SE, Reuben A. Rituximab-responsive cryoglobulinemic glomerulonephritis in a patient with autoimmune hepatitis. J Clin Gastroenterol 2008; 42: 862-3.
111. Smith MR. Rituximab (monoclonal anti-CD120 antibody): mechanisms of action and resisitance. Oncogene 2003; 22: 7539-68.
112. Burak K, Williamson-Coffey S, Swain M, et al. Rituximab for refractory autoimmune hepatitis: interim results of a phase 1 study. Canadian Digestive Disease Week 2009
113. Sehgal SN. Sirolimus: its discovery, biological properties and mechanism of action. Transplant Proc 2003; 35: S7-14
114. Kerkar N, Dugan C, Rumbo C, et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J transplant 2005; 5: 1085-9.
115. Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998; 29: 990-3.
116. Heneghan MA, Norris SM, O'Grady JG, et al. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001; 48: 97-102.
117. Samuel D, Riordan S, Strasser S, et al. Severe autoimmune hepatitis first presenting in the early post partum period. Clin Gastroenterol Hepatol 2004; 2: 622-4.
118. Werner M, Bjornsson E, Prytz H, et al. Autoimmune hepatitis among fertile women: stratgeies during pregnancy and breast feeding? Scand J Gastroenterol 2007; 42: 986-91.
119. Francella A, Dyan A, Bodian C, et al. The safety of 6-mercaptopurine for child bearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003; 124: 9-17.
120. Christopher V, Al-Chalabi T, Richardson PD, et al. Pregnancy outcome after liver transplantation: a single center experience of 71 pregnancies in 45 recipients. Liver Transpl 2006; 12: 1138-43.
121. Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int 2009; 29: 816-23.
122. Newton JL. Burt AD, Park JB, et al. Autoimmune hepatitis iin older patients. Age Ageing 1997; 26: 441-4.
123. Schramm C, Kanzler S, zum Buschenfelde KH, Galle PR, Lohse AW. Autoimmune hepatitis in the elderly. Am J Gastroenterol 2001; 96: 1587-91.
124. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006; 43: 532-8.